Product Description
Beraprost sodium (beraprost) is a stable, orally active prostacyclin analogue with vasodilatory, antiplatelet and cytoprotective effects. Beraprost acts by binding to prostacyclin membrane receptors ultimately inhibiting the release of Ca2+ from intracellular storage sites. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/11790158/)
Mechanisms of Action: PGI2 Angalogue
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Indonesia | Japan | Korea | Philippines | Thailand
Approved Indications: None
Company: Lung Biotechnology PBC
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Hypertension, Pulmonary|Type 2 Diabetes|Arteriosclerosis|Kidney Failure, Chronic
Phase 3: Kidney Diseases
Phase 2: Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension|Chronic Pain|Intermittent Claudication|Nephrosclerosis|Kidney Failure, Chronic
Phase 1: Healthy Volunteers|Hypertension|Chronic Pain|Kidney Diseases|Intermittent Claudication
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20230133 |
CTR20230133 | P2 |
Completed |
Intermittent Claudication|Chronic Pain |
2023-04-11 |
2025-04-29 |
Patient Enrollment|Treatments |
|
ChiCTR2500109121 |
ChiCTR2500109121 | N/A |
Not yet recruiting |
Ischemic Stroke |
2028-09-01 |
|||
ChiCTR2600129003 |
ChiCTR2600129003 | N/A |
Not yet recruiting |
Bronchiectasis|Hypertension, Pulmonary |
2028-07-07 |
|||
CTR20261183 |
CTR20261183 | N/A |
Completed |
Hypertension, Pulmonary |
2026-04-23 |
2026-05-24 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20255059 |
CTR20255059 | N/A |
Completed |
Chronic Pain|Intermittent Claudication |
2026-02-09 |
2026-02-15 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20240393 |
CTR20240393 | N/A |
Completed |
Chronic Pain|Intermittent Claudication |
2024-06-24 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20240237 |
CTR20240237 | N/A |
Completed |
Arterial Occlusive Diseases|Intermittent Claudication|Chronic Pain |
2024-04-20 |
2025-04-29 |
||
CTR20234207 |
CTR20234207 | N/A |
Completed |
Chronic Pain |
2024-02-28 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20233913 |
CTR20233913 | N/A |
Completed |
Chronic Pain |
2024-02-18 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20232567 |
CTR20232567 | N/A |
Completed |
Chronic Pain|Intermittent Claudication |
2023-10-26 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20232863 |
CTR20232863 | N/A |
Completed |
Hypertension, Pulmonary |
2023-09-29 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20232005 |
CTR20232005 | N/A |
Completed |
Hypertension, Pulmonary |
2023-08-04 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20230795 |
CTR20230795 | N/A |
Completed |
Intermittent Claudication|Chronic Pain |
2023-06-29 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20230861 |
CTR20230861 | N/A |
Completed |
Chronic Pain |
2023-05-27 |
2025-04-29 |
||
CTR20230860 |
CTR20230860 | N/A |
Completed |
Chronic Pain |
2023-04-21 |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20222993 |
CTR20222993 | N/A |
Completed |
Intermittent Claudication|Chronic Pain |
2023-04-06 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20230135 |
CTR20230135 | P1 |
Completed |
Intermittent Claudication|Chronic Pain |
2023-03-27 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20222321 |
CTR20222321 | N/A |
Completed |
Intermittent Claudication|Chronic Pain |
2023-01-09 |
2025-04-29 |
Patient Enrollment|Treatments |
|
NCT05103813 |
Beraprost Sodium treat STEMI | P1 |
Unknown status |
Hypertension |
2022-12-31 |
2023-10-03 |
Primary Endpoints|Treatments|Trial Status |
|
ChiCTR2000040599 |
ChiCTR2000040599 | N/A |
Not yet recruiting |
Anuria |
2022-12-31 |
|||
CTR20230066 |
CTR20230066 | N/A |
Completed |
Chronic Pain|Intermittent Claudication |
2022-11-27 |
2025-04-29 |
||
CTR20222753 |
CTR20222753 | N/A |
Completed |
Intermittent Claudication|Chronic Pain |
2022-11-26 |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20220217 |
CTR20220217 | N/A |
Completed |
Chronic Pain|Intermittent Claudication |
2022-08-30 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20220290 |
CTR20220290 | N/A |
Completed |
Chronic Pain|Intermittent Claudication |
2022-05-19 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20211566 |
CTR20211566 | P1 |
Completed |
Intermittent Claudication|Chronic Pain |
2022-04-20 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/22/2023 |
News Article |
Prostacyclin Market Share, Size 2023 Industry Overview, Comprehensive Research Study, Competitive Landscape 2023-2030 |